Evidence on the effectiveness of screening for prostate cancer

The aim of the study was to develop a mathematical model to estimate the costs, benefits and resource implications of alternative screening options for prostate cancer in the UK.

The impacts of four screening options using the prostate specific antigen (PSA) blood test conducted are assessed in comparison to no screening and to each other:

a single screen at age 50 years,
screening every four years from age 50 to 74 years,
screening every two years from age 50 to 74 years,
screening every year from age 50 to 74 years.

In addition a range of further screening options investigating the impact of screening at different ages and over different durations have also been examined.

Evidence on the effectiveness of screening for prostate cancer

The aim of the study was to develop a mathematical model to estimate the costs, benefits and resource implications of alternative screening options for prostate cancer in the UK.

Related Items

Strategic Planning

Clinical Operations

Population Health